The document summarizes Bayer's Q4 2011 and full year 2011 financial results and performance. It provides an overview of Bayer's sales, EBITDA, net income, cash flow and earnings per share for Q4 2011. It also discusses the performance of Bayer's business segments - HealthCare, CropScience and MaterialScience. Additionally, it reviews Bayer's progress on key pipeline projects in Pharma with potential to be blockbuster drugs. Bayer achieved its full year 2011 targets for sales, EBITDA, core EPS and net debt reduction.
The document is Aetna's 2005 annual report. It summarizes that 2005 was a successful year for Aetna with 13% revenue growth to $22.5 billion. Medical membership increased by over 1 million members which was primarily organic growth. Aetna also saw strong growth in dental and pharmacy membership. The company managed a commercial risk medical cost trend of over 8% while maintaining one of the best medical cost ratios in the industry at 78.4%, excluding prior period reserve development.
cardinal health Q4 2007 Earnings Presentationfinance2
This document summarizes Cardinal Health's fourth quarter and full year 2007 earnings results. For the fourth quarter, revenue increased 5% to $22.3 billion while operating earnings decreased 14% to $421 million. For the full year, revenue increased 9% to $86.9 billion while operating earnings decreased 26% to $1.4 billion. Segment results were mixed, with the Clinical Technologies and Services and Medical Products Manufacturing segments exceeding profit growth targets while the Healthcare Supply Chain Services segments were below or near targets. Cardinal Health provided financial targets for fiscal year 2008, forecasting continued revenue and earnings growth led by acquisitions and organic growth across segments.
The document provides an investor update on AkzoNobel's Q3 2012 results. It includes the following key information:
1) EBITDA was up 7% at €540 million despite a 3% decline in volumes primarily due to the economic slowdown in Europe. Revenue was up 6% mainly driven by currencies and pricing actions.
2) A €2.5 billion impairment charge related to Decorative Paints intangible assets resulted in a net loss of €2.4 billion for the quarter. Adjusted EPS was €1.01.
3) The performance improvement program is on track but the economic environment remains a principal sensitivity given the continued weak demand and cautious customer ordering patterns.
Hexion Chemicals held a conference on March 25, 2008 to discuss its financial results and outlook. The presentation contained forward-looking statements and non-GAAP financial measures with reconciliations provided. Hexion achieved strong revenue and earnings growth in 2007 driven by diversification across segments, geographies, and end markets. Management expects volatility in raw material costs to continue into 2008 and remains focused on productivity initiatives, synergies, and strategic acquisitions to fuel further growth.
Celanese Corporation reported third quarter results for 2008 with increases in net sales, operating profit, and earnings per share compared to the previous year. However, the company adjusted its full year 2008 outlook downward due to expectations of continued economic slowdown in North America and Europe negatively impacting volumes. Net sales increased 16% to $1.82 billion driven by higher pricing and volumes, while operating profit rose to $151 million. Earnings per share increased to $1.01. The company expects full year adjusted earnings per share between $3.40-$3.55, down from previous guidance, and operating EBITDA between $1.32-$1.355 billion.
Dean Foods reported financial results for the fourth quarter and full year of 2008. The company had strong profit growth in the fourth quarter, with adjusted operating income increasing 27% compared to the fourth quarter of 2007. For the full year, Dean Foods recovered from a weak first quarter, with adjusted operating income growing 7% despite high dairy commodity costs. The company significantly reduced debt in 2008 and expects continued earnings growth in 2009, led by the DSD Dairy and WhiteWave-Morningstar segments. Dean Foods is well positioned for 2009 despite volatility in dairy markets.
Ideagen reported preliminary results that exceeded expectations, with revenue of £2.3m, adjusted PBT of £0.5m, and net cash of £0.8m. Ideagen has rebranded and restructured its recent acquisitions under a single Ideagen brand focused on content management. It expects continued organic and acquisition growth in the fragmented UK market. The company delivered results ahead of forecasts and maintains a net cash position, setting a positive tone for future performance.
Abengoa presented its 2011 earnings and provided an outlook for 2012. Key highlights included:
- Revenues increased 46% to 7,089 million euros and EBITDA grew 36% to 1,103 million euros in 2011.
- The company's backlog remained strong at 7.5 billion euros at the end of 2011.
- Abengoa is diversifying its business across regions and sectors through new projects in the solar, transmission, and water industries.
- The company aims to further reduce debt and continue growing through international expansion in 2012.
The document is Aetna's 2005 annual report. It summarizes that 2005 was a successful year for Aetna with 13% revenue growth to $22.5 billion. Medical membership increased by over 1 million members which was primarily organic growth. Aetna also saw strong growth in dental and pharmacy membership. The company managed a commercial risk medical cost trend of over 8% while maintaining one of the best medical cost ratios in the industry at 78.4%, excluding prior period reserve development.
cardinal health Q4 2007 Earnings Presentationfinance2
This document summarizes Cardinal Health's fourth quarter and full year 2007 earnings results. For the fourth quarter, revenue increased 5% to $22.3 billion while operating earnings decreased 14% to $421 million. For the full year, revenue increased 9% to $86.9 billion while operating earnings decreased 26% to $1.4 billion. Segment results were mixed, with the Clinical Technologies and Services and Medical Products Manufacturing segments exceeding profit growth targets while the Healthcare Supply Chain Services segments were below or near targets. Cardinal Health provided financial targets for fiscal year 2008, forecasting continued revenue and earnings growth led by acquisitions and organic growth across segments.
The document provides an investor update on AkzoNobel's Q3 2012 results. It includes the following key information:
1) EBITDA was up 7% at €540 million despite a 3% decline in volumes primarily due to the economic slowdown in Europe. Revenue was up 6% mainly driven by currencies and pricing actions.
2) A €2.5 billion impairment charge related to Decorative Paints intangible assets resulted in a net loss of €2.4 billion for the quarter. Adjusted EPS was €1.01.
3) The performance improvement program is on track but the economic environment remains a principal sensitivity given the continued weak demand and cautious customer ordering patterns.
Hexion Chemicals held a conference on March 25, 2008 to discuss its financial results and outlook. The presentation contained forward-looking statements and non-GAAP financial measures with reconciliations provided. Hexion achieved strong revenue and earnings growth in 2007 driven by diversification across segments, geographies, and end markets. Management expects volatility in raw material costs to continue into 2008 and remains focused on productivity initiatives, synergies, and strategic acquisitions to fuel further growth.
Celanese Corporation reported third quarter results for 2008 with increases in net sales, operating profit, and earnings per share compared to the previous year. However, the company adjusted its full year 2008 outlook downward due to expectations of continued economic slowdown in North America and Europe negatively impacting volumes. Net sales increased 16% to $1.82 billion driven by higher pricing and volumes, while operating profit rose to $151 million. Earnings per share increased to $1.01. The company expects full year adjusted earnings per share between $3.40-$3.55, down from previous guidance, and operating EBITDA between $1.32-$1.355 billion.
Dean Foods reported financial results for the fourth quarter and full year of 2008. The company had strong profit growth in the fourth quarter, with adjusted operating income increasing 27% compared to the fourth quarter of 2007. For the full year, Dean Foods recovered from a weak first quarter, with adjusted operating income growing 7% despite high dairy commodity costs. The company significantly reduced debt in 2008 and expects continued earnings growth in 2009, led by the DSD Dairy and WhiteWave-Morningstar segments. Dean Foods is well positioned for 2009 despite volatility in dairy markets.
Ideagen reported preliminary results that exceeded expectations, with revenue of £2.3m, adjusted PBT of £0.5m, and net cash of £0.8m. Ideagen has rebranded and restructured its recent acquisitions under a single Ideagen brand focused on content management. It expects continued organic and acquisition growth in the fragmented UK market. The company delivered results ahead of forecasts and maintains a net cash position, setting a positive tone for future performance.
Abengoa presented its 2011 earnings and provided an outlook for 2012. Key highlights included:
- Revenues increased 46% to 7,089 million euros and EBITDA grew 36% to 1,103 million euros in 2011.
- The company's backlog remained strong at 7.5 billion euros at the end of 2011.
- Abengoa is diversifying its business across regions and sectors through new projects in the solar, transmission, and water industries.
- The company aims to further reduce debt and continue growing through international expansion in 2012.
The SGS Group posted a strong first semester performance with revenue growth of 15.1% over prior year to CHF 2.7 billion (constant currency basis), reflecting both organic revenue growth of 11.1% and the integration of twenty four recently acquired companies contributing an additional 4.0% in revenues.
MeadWestvaco reported financial results for the fourth quarter and full year of 2007. For the full year, sales increased 6% to $6.9 billion and business segment profit rose 7% to $584 million. The company sold non-strategic forestlands, completed a $400 million share buyback, and strengthened its global packaging platform. Input costs increased significantly but the company implemented price increases across all major grades to offset these costs. For the fourth quarter, sales rose 4% while business segment profit declined 3% due to higher input costs and weaker demand in some segments.
Duke Energy reported first quarter 2006 results, with ongoing diluted EPS of 48 cents, up from 43 cents in the prior year. Reported diluted EPS was 37 cents compared to 88 cents last year. Results improved at Franchised Electric, Natural Gas Transmission, and International Energy segments due to factors like customer growth, currency impacts, and improved prices and volumes. Duke Energy is on track to achieve its 2006 target of $1.90 in ongoing diluted EPS and remains comfortable after merging with Cinergy that it can achieve this target for the combined company.
This document discusses managed services and how ARAMARK provides value through various services. It highlights:
1) ARAMARK is a leading provider of food, facilities, and uniform services to business, education, healthcare, government, and sports/entertainment clients. It generates strong cash flow and returns capital to shareholders.
2) ARAMARK adds value for clients by improving customer satisfaction, outcomes important to clients, and cost efficiencies. It has opportunities for growth through additional client penetration, higher usage at existing clients, new services, and international expansion.
3) ARAMARK maintains financial discipline and targets long-term organic growth, margin expansion, and EPS growth to drive shareholder returns.
This document discusses managed services and how ARAMARK provides value as a managed services leader. It highlights ARAMARK's financial performance, growth opportunities, and operating model. The key points are:
1) ARAMARK is a leading provider of food, facilities, and uniform services to various clients. It has a diverse client base and international presence.
2) ARAMARK adds value for clients by improving customer satisfaction, outcomes important to clients, and cost efficiencies. It also has opportunities for growth through additional client penetration, service expansion, and international growth.
3) ARAMARK has a disciplined operating model and financial targets, including 6-8% organic growth and 12-14% EPS
- Ameriprise Financial reported a 14% increase in net income for Q1 2007 to $165 million compared to Q1 2006. Adjusted earnings, which exclude non-recurring separation costs, increased 16% to $220 million.
- Revenues grew 6% to $2.1 billion, driven by 11% growth in management fees and 14% growth in distribution fees. However, net investment income declined 10% due to lower balances in annuity fixed accounts and certificates.
- Earnings growth was achieved through a strategic shift toward fee-based products and greater advisor productivity, though this was partially offset by declines in spread income from annuity and certificate businesses.
The document summarizes Duke Energy's first quarter 2006 earnings review presentation. It discusses Duke Energy and Cinergy's first quarter results, including higher ongoing earnings compared to the previous year for most business segments. It also discusses the companies' commitments to investors around growing earnings, achieving full portfolio value, and transparent communication. Key highlights are Duke Energy's continued progress exiting the DENA business and confidence in Cinergy contributing $800 million in ongoing EBIT for the remaining year.
The document provides supplemental financial schedules for Occidental Petroleum for 4Q 2008, 4Q 2007, and full year 2008 and 2007. It shows reported net income and core results, with reconciling items between the two. Some key figures:
- 4Q 2008 reported net income was $443 million, core results were $957 million
- 4Q 2007 reported net income was $1,452 million, core results were $1,464 million
- Full year 2008 reported net income was $6,857 million, core results were $7,348 million
- Full year 2007 reported net income was $5,400 million, core results were $4,405 million
The document is a presentation of BG Group's 2012 results. It provides highlights such as a 4% increase in total operating profit to $8.047 billion, with upstream profit of $5.464 billion. It discusses financial results, strategic priorities for 2013 including production delivery and major project milestones. Key capital expenditure projects are outlined along with a $10.4 billion cash capex budget and $8.1 billion in portfolio rationalization by end of 2013. Safety and operational performance are reviewed along with 2013 production outlook of 630-660 kboed.
This document summarizes Hexion's first quarter 2007 earnings conference call. Key points include:
- Revenues increased 17% over the prior year to $1.438 billion, driven by price increases and acquisitions.
- Segment EBITDA increased 29% to $170 million compared to the prior year.
- Raw material costs increased but pricing initiatives helped offset this.
- $11 million in synergies were achieved in Q1 2007, putting Hexion on track to achieve $175 million in targeted synergies.
- The integration of the Orica acquisition is proceeding as planned.
Cadila Healthcare reported strong results for the second quarter of fiscal year 2011. Net sales increased 21.2% year-over-year to 1,106 crore, ahead of analyst estimates, driven by growth in the domestic formulation, US, and Brazil businesses. Operating profit margin expanded to 21.2% compared to 18.9% in the prior year quarter, due to a favorable product mix and lower selling, general, and administrative expenses. Net profit grew 29.5% to 171 crore. For fiscal year 2011, the company reiterated its guidance of 27-28% revenue growth to 4,300-4,600 crore and a 100 basis point improvement in operating profit margin.
Celanese Corporation reported strong fourth quarter and full year 2005 results, with net sales up 19% and 22% respectively. Adjusted earnings per share for the fourth quarter were $0.60, exceeding guidance, and $2.24 for the full year. Adjusted EBITDA rose 40% for the quarter and 44% for the full year due to higher pricing, productivity improvements, and acquisitions offsetting increased costs. For 2006, the company reaffirmed adjusted EPS guidance of $2.50 to $2.90.
1) The document reports Monsanto's financial results for the fourth quarter and fiscal year 2007, noting record sales and profits.
2) Net income decreased 46% in Q4 2007 compared to Q4 2006, but increased 44% for the fiscal year. Ongoing EPS grew 54% for the fiscal year.
3) Monsanto extended its leadership in seeds and traits in 2007 through various initiatives, and its pipeline has potential blockbuster traits and opportunities for further global expansion of existing biotech traits.
The document summarizes Duke Energy's financial results for the third quarter of 2005. It reports higher earnings in the company's franchised electric, natural gas transmission, and international energy segments. It also discusses the financial impacts of Duke Energy's decision to exit its North American commercial power business. Finally, it provides expectations for 2005 ongoing earnings per share and 2007 ongoing earnings following the planned merger with Cinergy.
- Deutsche Telekom reported Q1 2012 results with group revenue of €14.4 billion, a 1.1% decline year-over-year, but an improved organic decline of 1.7%. Adjusted EBITDA was stable at €4.5 billion.
- In Germany, revenue declined 2.3% organically due to lower voice and wholesale revenues, but adjusted EBITDA margin improved further to 40.7% due to cost savings. Mobile data revenue grew 20% and smartphone sales were strong.
- In the US, revenues declined 2.3% in US dollars but adjusted EBITDA grew 8% to US$1.3 billion due to cost reductions, with the margin improving
A Brief Introduction to Ruby & Mid-90s Hip HopDavid Eisinger
The document discusses various Ruby programming concepts including system commands, methods, arrays, cases, classes, and blocks. It provides code examples to demonstrate how to use system commands to run external programs and copy files, define and call methods, work with arrays and cases, create and access attributes in a class, and pass blocks to methods to run code.
This investor handout provides an overview of Bayer's financial performance in Q1 2012 and outlook for 2012. Key points include:
- Sales and earnings grew in Q1 2012 compared to Q1 2011, with a 5% increase in sales and double-digit increases in EBIT and EPS.
- The outlook for 2012 projects further sales and earnings growth, with sales expected to increase around 3% and EBITDA and EPS expected to slightly improve.
- Bayer has mid-term targets through 2014 to increase sales and profitability across its business segments, focusing on innovation, growth, and productivity.
Email Interfaces for your Ruby ApplicationsDavid Eisinger
This document discusses using email interfaces for Ruby applications. Some key points covered include:
- Email is ubiquitous and can provide inherent attention and gradual engagement. It also allows embedding identity and resurrecting dead data.
- Elements of an email interface include the TO address, subject line, message body, and attachments.
- Receiving email involves tools like Postfix and POP/IMAP for fetching messages, then processing them using libraries like TMail and mms2r.
- Testing email interfaces requires fixtures to ensure proper functionality.
This document summarizes Bayer's Q3 2012 results and provides an outlook for fiscal year 2012. Key points include:
1) Bayer's HealthCare and CropScience divisions continued their upward trends in Q3 2012, though reported earnings were impacted by special charges.
2) The company's innovation pipeline made significant progress and strategic acquisitions were completed in Q3.
3) Financial outlook for 2012 is reiterated, with core EPS expected to increase approximately 10% over 2011.
The SGS Group posted a strong first semester performance with revenue growth of 15.1% over prior year to CHF 2.7 billion (constant currency basis), reflecting both organic revenue growth of 11.1% and the integration of twenty four recently acquired companies contributing an additional 4.0% in revenues.
MeadWestvaco reported financial results for the fourth quarter and full year of 2007. For the full year, sales increased 6% to $6.9 billion and business segment profit rose 7% to $584 million. The company sold non-strategic forestlands, completed a $400 million share buyback, and strengthened its global packaging platform. Input costs increased significantly but the company implemented price increases across all major grades to offset these costs. For the fourth quarter, sales rose 4% while business segment profit declined 3% due to higher input costs and weaker demand in some segments.
Duke Energy reported first quarter 2006 results, with ongoing diluted EPS of 48 cents, up from 43 cents in the prior year. Reported diluted EPS was 37 cents compared to 88 cents last year. Results improved at Franchised Electric, Natural Gas Transmission, and International Energy segments due to factors like customer growth, currency impacts, and improved prices and volumes. Duke Energy is on track to achieve its 2006 target of $1.90 in ongoing diluted EPS and remains comfortable after merging with Cinergy that it can achieve this target for the combined company.
This document discusses managed services and how ARAMARK provides value through various services. It highlights:
1) ARAMARK is a leading provider of food, facilities, and uniform services to business, education, healthcare, government, and sports/entertainment clients. It generates strong cash flow and returns capital to shareholders.
2) ARAMARK adds value for clients by improving customer satisfaction, outcomes important to clients, and cost efficiencies. It has opportunities for growth through additional client penetration, higher usage at existing clients, new services, and international expansion.
3) ARAMARK maintains financial discipline and targets long-term organic growth, margin expansion, and EPS growth to drive shareholder returns.
This document discusses managed services and how ARAMARK provides value as a managed services leader. It highlights ARAMARK's financial performance, growth opportunities, and operating model. The key points are:
1) ARAMARK is a leading provider of food, facilities, and uniform services to various clients. It has a diverse client base and international presence.
2) ARAMARK adds value for clients by improving customer satisfaction, outcomes important to clients, and cost efficiencies. It also has opportunities for growth through additional client penetration, service expansion, and international growth.
3) ARAMARK has a disciplined operating model and financial targets, including 6-8% organic growth and 12-14% EPS
- Ameriprise Financial reported a 14% increase in net income for Q1 2007 to $165 million compared to Q1 2006. Adjusted earnings, which exclude non-recurring separation costs, increased 16% to $220 million.
- Revenues grew 6% to $2.1 billion, driven by 11% growth in management fees and 14% growth in distribution fees. However, net investment income declined 10% due to lower balances in annuity fixed accounts and certificates.
- Earnings growth was achieved through a strategic shift toward fee-based products and greater advisor productivity, though this was partially offset by declines in spread income from annuity and certificate businesses.
The document summarizes Duke Energy's first quarter 2006 earnings review presentation. It discusses Duke Energy and Cinergy's first quarter results, including higher ongoing earnings compared to the previous year for most business segments. It also discusses the companies' commitments to investors around growing earnings, achieving full portfolio value, and transparent communication. Key highlights are Duke Energy's continued progress exiting the DENA business and confidence in Cinergy contributing $800 million in ongoing EBIT for the remaining year.
The document provides supplemental financial schedules for Occidental Petroleum for 4Q 2008, 4Q 2007, and full year 2008 and 2007. It shows reported net income and core results, with reconciling items between the two. Some key figures:
- 4Q 2008 reported net income was $443 million, core results were $957 million
- 4Q 2007 reported net income was $1,452 million, core results were $1,464 million
- Full year 2008 reported net income was $6,857 million, core results were $7,348 million
- Full year 2007 reported net income was $5,400 million, core results were $4,405 million
The document is a presentation of BG Group's 2012 results. It provides highlights such as a 4% increase in total operating profit to $8.047 billion, with upstream profit of $5.464 billion. It discusses financial results, strategic priorities for 2013 including production delivery and major project milestones. Key capital expenditure projects are outlined along with a $10.4 billion cash capex budget and $8.1 billion in portfolio rationalization by end of 2013. Safety and operational performance are reviewed along with 2013 production outlook of 630-660 kboed.
This document summarizes Hexion's first quarter 2007 earnings conference call. Key points include:
- Revenues increased 17% over the prior year to $1.438 billion, driven by price increases and acquisitions.
- Segment EBITDA increased 29% to $170 million compared to the prior year.
- Raw material costs increased but pricing initiatives helped offset this.
- $11 million in synergies were achieved in Q1 2007, putting Hexion on track to achieve $175 million in targeted synergies.
- The integration of the Orica acquisition is proceeding as planned.
Cadila Healthcare reported strong results for the second quarter of fiscal year 2011. Net sales increased 21.2% year-over-year to 1,106 crore, ahead of analyst estimates, driven by growth in the domestic formulation, US, and Brazil businesses. Operating profit margin expanded to 21.2% compared to 18.9% in the prior year quarter, due to a favorable product mix and lower selling, general, and administrative expenses. Net profit grew 29.5% to 171 crore. For fiscal year 2011, the company reiterated its guidance of 27-28% revenue growth to 4,300-4,600 crore and a 100 basis point improvement in operating profit margin.
Celanese Corporation reported strong fourth quarter and full year 2005 results, with net sales up 19% and 22% respectively. Adjusted earnings per share for the fourth quarter were $0.60, exceeding guidance, and $2.24 for the full year. Adjusted EBITDA rose 40% for the quarter and 44% for the full year due to higher pricing, productivity improvements, and acquisitions offsetting increased costs. For 2006, the company reaffirmed adjusted EPS guidance of $2.50 to $2.90.
1) The document reports Monsanto's financial results for the fourth quarter and fiscal year 2007, noting record sales and profits.
2) Net income decreased 46% in Q4 2007 compared to Q4 2006, but increased 44% for the fiscal year. Ongoing EPS grew 54% for the fiscal year.
3) Monsanto extended its leadership in seeds and traits in 2007 through various initiatives, and its pipeline has potential blockbuster traits and opportunities for further global expansion of existing biotech traits.
The document summarizes Duke Energy's financial results for the third quarter of 2005. It reports higher earnings in the company's franchised electric, natural gas transmission, and international energy segments. It also discusses the financial impacts of Duke Energy's decision to exit its North American commercial power business. Finally, it provides expectations for 2005 ongoing earnings per share and 2007 ongoing earnings following the planned merger with Cinergy.
- Deutsche Telekom reported Q1 2012 results with group revenue of €14.4 billion, a 1.1% decline year-over-year, but an improved organic decline of 1.7%. Adjusted EBITDA was stable at €4.5 billion.
- In Germany, revenue declined 2.3% organically due to lower voice and wholesale revenues, but adjusted EBITDA margin improved further to 40.7% due to cost savings. Mobile data revenue grew 20% and smartphone sales were strong.
- In the US, revenues declined 2.3% in US dollars but adjusted EBITDA grew 8% to US$1.3 billion due to cost reductions, with the margin improving
A Brief Introduction to Ruby & Mid-90s Hip HopDavid Eisinger
The document discusses various Ruby programming concepts including system commands, methods, arrays, cases, classes, and blocks. It provides code examples to demonstrate how to use system commands to run external programs and copy files, define and call methods, work with arrays and cases, create and access attributes in a class, and pass blocks to methods to run code.
This investor handout provides an overview of Bayer's financial performance in Q1 2012 and outlook for 2012. Key points include:
- Sales and earnings grew in Q1 2012 compared to Q1 2011, with a 5% increase in sales and double-digit increases in EBIT and EPS.
- The outlook for 2012 projects further sales and earnings growth, with sales expected to increase around 3% and EBITDA and EPS expected to slightly improve.
- Bayer has mid-term targets through 2014 to increase sales and profitability across its business segments, focusing on innovation, growth, and productivity.
Email Interfaces for your Ruby ApplicationsDavid Eisinger
This document discusses using email interfaces for Ruby applications. Some key points covered include:
- Email is ubiquitous and can provide inherent attention and gradual engagement. It also allows embedding identity and resurrecting dead data.
- Elements of an email interface include the TO address, subject line, message body, and attachments.
- Receiving email involves tools like Postfix and POP/IMAP for fetching messages, then processing them using libraries like TMail and mms2r.
- Testing email interfaces requires fixtures to ensure proper functionality.
This document summarizes Bayer's Q3 2012 results and provides an outlook for fiscal year 2012. Key points include:
1) Bayer's HealthCare and CropScience divisions continued their upward trends in Q3 2012, though reported earnings were impacted by special charges.
2) The company's innovation pipeline made significant progress and strategic acquisitions were completed in Q3.
3) Financial outlook for 2012 is reiterated, with core EPS expected to increase approximately 10% over 2011.
Marijn Dekkers, CEO of Bayer, discussed the company's Q1 2013 results in an investor conference call. Bayer's LifeScience businesses performed well, with Healthcare benefiting from new product launches and Consumer Care growth. CropScience continued growing profitably in a favorable market. However, cost pressure at MaterialScience resulted in earnings below expectations. Overall, Bayer's Q1 sales grew 4% organically and EBIT increased 9%. The company confirmed its full-year 2013 outlook of mid-single-digit adjusted EBITDA growth and high-single-digit core EPS growth.
- Bayer confirms full-year 2011 Group financial outlook of 5-7% organic sales growth, adjusted EBITDA over €7.5 billion, and core EPS growth of approximately 15%.
- In Q3 2011, Bayer delivered sales growth of 1% (5% adjusted for currency and portfolio effects) and adjusted EBITDA growth of 8% compared to the prior year.
- Reported net income increased 125% to €642 million compared to Q3 2010, driven by continued momentum in emerging markets and productivity measures.
- Bayer reported positive Q3 2011 results, with adjusted sales up 5% and adjusted EBITDA up 8%
- Key strategic progress included positive regulatory milestones for new drugs and 10% organic growth in emerging markets
- Bayer reiterated full-year outlook of 5-7% organic sales growth, adjusted EBITDA over €7.5 billion, and core EPS growth of approximately 15%
Q2 2011 Investor Handout U.S. West Coast RoadshowBayer
The document summarizes a presentation by Bayer's CFO Werner Baumann to investors on the company's performance in the second quarter of 2011 and outlook. Key points include:
1) Bayer continued positive momentum in the second quarter with sales growth of 5% and adjusted EBITDA growth of 6%.
2) The company reiterated its outlook for higher sales and adjusted EBITDA in 2011.
3) Bayer plans to invest €15 billion through 2013 to maximize the value of its new product pipeline and realize opportunities in emerging markets.
This document summarizes Bayer's Q2 2012 results. It saw record sales but lower reported EBIT due to special charges. All business segments saw strong growth. Full year 2012 guidance was raised significantly, expecting 4-5% organic sales growth and around a 10% increase in core EPS. Regional performance was led by the US and emerging markets. Cash flow was down year-over-year but net debt decreased. Outlooks for each subgroup were also raised for the fiscal year.
This document provides an agenda and details for an analyst presentation. It summarizes 2010 preliminary figures that showed record-breaking achievements including double-digit growth and surpassing €150 million in performance. It outlines Terna's strategic update, which focuses on both traditional regulated grid activities as well as new non-traditional initiatives in renewable energy, storage, and efficiency. Finally, it presents 2011-2015 strategic targets, which include increasing capex to €5 billion, achieving an EBITDA margin of 78%, and growing the RAB at a CAGR of 6.6% through continued investment.
CPFL Energia reported strong financial results for the 1st quarter of 2005. Net income increased to R$166 million compared to a net loss of R$12 million in the prior year. EBITDA grew 21% and gross revenue increased 14%. Energy sales rose 4.3% while demand in the concession area grew 7.3%. The company expects continued growth in energy sales and efficient management. Business outlook includes increasing generation capacity and focus on debt profile and corporate governance.
The document provides an overview of Banco Popular Español's 1st half 2012 results presentation. Key highlights include achieving best-in-class recurrent revenues and pre-provision profit. Efficiency ratios improved further to 38.5% in 1H12. Strong provisioning increased coverage ratios to 56% while EBA core tier 1 capital ratio reached 10.3%, beating targets. Business plan was approved by the board of directors positioning the bank well for upcoming stress tests.
The document discusses forward-looking statements and outlines risks associated with them. It notes that forward-looking statements are based on assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from expectations. The document also provides contact information for investor relations.
cardinal health Q1 2008 Earnings Presentationfinance2
This document summarizes Cardinal Health's Q1 FY2008 earnings call from November 5, 2007.
- Consolidated revenue grew 5% year-over-year to $21.973 billion, while non-GAAP operating earnings grew 8% to $512 million and non-GAAP diluted EPS grew 15% to $0.86.
- Healthcare Supply Chain Services pharmaceutical revenue grew 4% to $19.221 billion, while segment profit grew 6% to $305 million. Medical revenue grew 6% to $1.921 billion, while segment profit declined 10% to $58 million.
- Cardinal Health is reconfirming its non-GAAP EPS guidance range of $3
cardinal health Conference Call Presentationfinance2
This document contains the key details from Cardinal Health's Q1 FY2009 investor call on October 29, 2008. It discusses Cardinal's financial results for Q1, including revenue of $24.3 billion (up 11% year-over-year) and operating earnings of $426 million (down 13% year-over-year). It also provides updates on Cardinal's Healthcare Supply Chain Services and Clinical and Medical Products segments. The document outlines Cardinal's financial goals for FY2009 and assumptions, and addresses questions from analysts on the call.
This document is the transcript from an investor conference call by Marijn Dekkers, CEO of a science and technology company, reporting on Q2 2011 results. Dekkers discusses financial results including 5% group sales growth. Sales increased the most in emerging economies at 7% and the US at 4%. Guidance is provided for 2011 subgroups with HealthCare, Pharma and Consumer Health expected to see low to mid single digit sales growth. CropScience sales are forecast to increase by a high single digit percentage and MaterialScience sales to increase at a higher rate than sales.
- Bayer reported strong 2014 financial results, meeting or exceeding guidance across key metrics like sales, adjusted EBITDA, and core EPS.
- Q4 2014 continued the positive performance, with all business segments contributing to growth.
- For 2015, Bayer expects further sales and earnings growth, with sales increasing in the low single digits and adjusted EBITDA rising 10-15%.
- R&D and capital expenditure budgets are increasing to drive new product innovation across key areas like pharmaceuticals and crop science.
- Novartis reported strong sales and operating income growth in Q2 2011, with net sales up 19% in constant currencies and core operating income up 30% in constant currencies.
- The company achieved four major drug approvals in Q2 2011 across its pharmaceuticals, Alcon, and Sandoz divisions.
- Novartis has diversified its portfolio through acquisitions and is focusing on strategic priorities like innovation, growth in emerging markets, and improving productivity to drive margins.
air products & chemicals fy 08 q2 earningsfinance26
- Air Products reported a 40% increase in quarterly EPS to $1.43 per share and a 38% increase in net income to $314 million for its fiscal second quarter.
- Revenues increased 13% to $2.6 billion due to higher volumes in Tonnage Gases and Electronics and Performance Materials as well as higher pricing in Merchant Gases.
- Based on strong first half performance, Air Products raised its full year EPS guidance to a range of $4.95 to $5.05 per share, representing 18-20% annual growth.
This document summarizes Raytheon's financial results for the fourth quarter and full year of 2008. Key points include: Raytheon reported solid financial results for Q4 and full year 2008, with record backlog of $38.9 billion; Q4 sales were $6.1 billion and adjusted EPS was $1.13; Full year sales grew 9% to $23.2 billion and adjusted EPS grew 23% to $4.06; Raytheon reaffirmed its financial guidance for 2009 and expects continued growth.
Bayer held an investor conference call to discuss its FY/Q4 2015 results. In 2015, Bayer achieved higher sales, strong adjusted EBITDA growth, and higher core EPS compared to 2014. Q4 2015 performance was mixed, with higher sales in key divisions but profit growth held back by investments and a challenging agriculture environment. For 2016, Bayer forecasts further sales and earnings growth for the group and its divisions.
Ferrovial reported its 2011 full year results. The document contained forward-looking statements that are based on estimates and assumptions, and are subject to risks and uncertainties. Analysts and investors are cautioned not to place undue reliance on forward-looking statements.
Ferrovial had a strong year of cash generation, debt reduction, and divestments. Key highlights included over €1.4 billion in cash flow excluding infrastructure projects, a net cash position of €907 million excluding projects, and value obtained from divestments exceeding market expectations. Business units reported revenue and EBITDA growth across most segments.
Looking ahead, Ferrovial is well positioned with a strong balance sheet and liquidity.
Presentación de Resultados Ferrovial 2011Ferrovial
Ferrovial reported its 2011 full year results. The document contained forward-looking statements that are based on estimates and assumptions, and are subject to risks and uncertainties. Analysts and investors are cautioned not to place undue reliance on forward-looking statements.
Ferrovial had a strong year of cash generation, debt reduction, and divestments. Key highlights included over €1.4 billion in cash flow excluding infrastructure projects, a net cash position of €907 million excluding projects, and value obtained from divestments exceeding market expectations. Business units reported revenue and EBITDA growth across most segments. Ferrovial is well positioned with a strong balance sheet and liquidity to invest in future growth opportunities
Similar to FY / Q4 2011 Investor Conference Call Presentation Charts (20)
This document provides an overview of Bayer's Q3 2023 investor webinar. Key points include:
- Q3 sales were below prior year due to currency headwinds, with core EPS and free cash flow also declining.
- Full year 2023 outlook is confirmed, with estimated currency impact reducing EBITDA.
- Crop Science sales declined year-over-year mainly due to lower glyphosate prices, though the core business grew with strong pricing.
- Pharmaceuticals sales grew slightly, with launch assets and Eylea performing well despite a soft mature portfolio.
- The pipeline is progressing with several studies starting or expected to report.
Crop Science sales are expected to decline 5% due to a 50% drop in glyphosate sales returning to 2020 levels, while the core business is forecast to grow 5-7%. Pharmaceutical sales are projected to be flat as growth from new products offsets declines. Consumer Health sales may rise 1% despite supply constraints. The outlook assumes €1.7bn in negative currency effects and €2-3bn in litigation settlement costs.
Bayer held an investor conference call on May 11th, 2023 to discuss financial results for Q1 2023 and provide an outlook for the full year. Key highlights include:
- Q1 2023 sales were €8.4 billion, down 2% year-over-year due to a decline in glyphosate sales, though the remaining portfolio grew by 8%.
- Full year 2023 guidance was confirmed towards the lower end of the previous range, with sales expected to grow 2-3% and EBITDA between €12.5-13 billion.
- Crop Science sales are expected to grow 1.5% for the full year, with a 30-35% decline in glyphosate
Bayer held an investor conference call to discuss its Q3 2022 results. The CEO and CFO provided an overview of the company's financial performance, with all divisions reporting sales and earnings growth. Bayer remains on track to meet its full-year guidance targets despite cost inflation. The presentations focused on business updates and divisional results for Crop Science, Pharmaceuticals, and Consumer Health. Forecasts were also confirmed for key financial metrics and each division's performance for full-year 2022.
Bayer hosted an investor conference call to report its Q2 2022 results and raise its full-year 2022 guidance. Key highlights include:
- Q2 sales increased 18% to €12.8 billion driven by double-digit growth across all divisions.
- Full-year 2022 group sales are expected to increase to €47-48 billion and EBITDA margin is forecast at 26-27%.
- Crop Science sales increased 29% in Q2 and full-year growth is expected to be around 13%. Strong pricing is outpacing cost inflation.
- Pharmaceuticals and Consumer Health also posted sales growth in Q2 and their full-year outlooks were increased.
- Higher sales and
This document summarizes the key points from an investor conference call for Bayer's Q1 2022 results. Bayer reported strong sales and earnings growth in Q1 2022, driven by double-digit increases in Crop Science. All divisions outpaced expectations. Bayer also confirmed full-year 2022 guidance, expecting continued sales growth of around 5% despite inflationary pressures. Key priorities for 2022 include maintaining supply chain stability and offsetting cost inflation through pricing and efficiency measures.
Bayer reported strong financial results for FY 2021 despite challenges from currency headwinds and inflation. Group sales increased 7% to €44.1 billion driven by growth across all divisions. Core EPS rose to €6.51. Bayer expects continued sales and earnings growth in 2022, forecasting sales of ~€46 billion and Core EPS of ~€7.00 at constant currencies. Key assumptions include mid-single digit growth in Crop Science and Consumer Health and low single digit growth in Pharmaceuticals.
The document provides a summary of Bayer's Q3 2021 investor conference call. Key highlights include:
- Bayer reported double-digit sales and earnings growth in Q3 2021, driven by strong performances in Crop Science and Consumer Health.
- Full-year 2021 guidance was updated to reflect increased sales growth expectations for Crop Science and Consumer Health, while other group KPI guidance remained unchanged.
- By division, Crop Science delivered particularly strong year-over-year growth in sales and earnings. Pharma and Consumer Health also progressed well despite currency headwinds.
So in summary, Bayer delivered a strong Q3 with sales and profit increases, led by Crop Science. Full-year guidance was
The document provides an investor conference call summary for Bayer's Q2 2021 results. It includes the following key points:
- Bayer increased its full-year 2021 guidance for sales, EBITDA margin, core EPS, and net financial debt due to strong first half performance.
- All business divisions (Crop Science, Pharmaceuticals, Consumer Health) contributed to sales growth in Q2 2021 and are expected to grow for the full year.
- EBITDA before special items was lower in Q2 2021 due to currency headwinds, but margins are expected to improve for the full year.
- Free cash flow was impacted by litigation settlement payouts of €0.9 billion
This document provides a summary of Bayer's Q1 2021 earnings results conference call. It includes:
1) Bayer reported solid sales growth in Q1 2021 driven by its Crop Science division, but currency headwinds masked the underlying performance.
2) All divisions showed good underlying momentum despite currency impacts, with Crop Science up 6% at constant currencies and Pharma flat at constant currencies.
3) Bayer reconfirmed its full-year 2021 outlook despite challenges in Q1, expecting sales of €42-43 billion, Core EPS of €6.10-€6.30, and free cash flow of €36-37 billion at constant currencies.
Bayer reported financial results for full-year and Q4 2020. Despite currency headwinds, the company achieved its updated guidance for sales, EBITDA margin, core EPS and free cash flow. For 2021, Bayer expects sales of €42-43 billion, an EBITDA margin of around 27%, and core EPS of €6.10-€6.30. However, currency effects are expected to reduce sales by around €2 billion and core EPS by around €0.50 compared to constant currencies. Free cash flow is guided to be negative €3-4 billion due to planned litigation settlements of around €8 billion.
Bayer reported third quarter 2020 results with sales down 5% currency-adjusted to €8.5 billion. EBITDA declined 21% to €1.8 billion due to negative currency effects and higher product returns in Crop Science. Core EPS fell 30% to €0.81 per share. The company confirmed its currency-adjusted full-year outlook despite challenges in Crop Science. Free cash flow was negative €2 million due to settlement payments.
Werner Baumann, CEO of Bayer, and Wolfgang Nickl, CFO of Bayer, presented results from Bayer's Q2 2020 investor conference call. Despite challenges from COVID-19, Bayer reported solid results with sales of €10.054 billion and EBITDA before special items of €2.883 billion, up 6% year-over-year. Free cash flow increased 87% year-over-year to €1.59 billion. For the second half of 2020, Bayer expects continued impacts from COVID-19 and is focusing on cash and cost management. Bayer updated full-year 2020 guidance with sales expected between €42-43 billion and free cash flow between -€0.
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Bayer
The document summarizes Bayer's Q1 2020 earnings results and provides an outlook for 2020. Key highlights include:
- Q1 sales increased 6% to €12.8 billion driven by growth in Crop Science and Pharmaceuticals. EBITDA rose 10% to €4.4 billion.
- All business segments saw increased demand related to the COVID-19 pandemic. Crop Science had strong growth in insecticides and herbicides. Pharmaceuticals was led by Xarelto growth. Consumer Health saw elevated demand across categories.
- The outlook acknowledges COVID-19 uncertainty and focuses on maintaining operations, progressing the pipeline, continuing integration efforts, and realizing efficiency programs. Net debt was largely unchanged from year
Bayer reported its FY/Q4 2019 results, achieving its guidance targets. Sales were €43.5 billion, EBITDA was €11.5 billion, and core EPS was €6.40. Each business division performed well, with Crop Science benefiting from integration synergies, Pharmaceuticals growing due to drugs like Xarelto and Eylea, and Consumer Health returning to peer growth. Bayer also progressed on portfolio measures, signing agreements to divest its Animal Health division and other smaller businesses. Looking ahead, Bayer provided guidance for 2020 of continued sales and earnings growth.
Bayer reported its Q3 2019 results with continued growth across all divisions. Key highlights include:
- Group sales increased 5% to €9.8 billion driven by strong growth in Pharmaceuticals and Crop Science.
- EBITDA before special items grew 8% to €2.3 billion with margins up 30 basis points.
- Core EPS increased 6% to €1.16. Free cash flow grew 13% to €1.3 billion.
- Guidance for 2019 was confirmed with sales of ~€46 billion, EBITDA before special items of ~€12.2 billion, and core EPS of ~€6.80.
Crop Science Summer Technology Showcase August 1, 2019Bayer
Keynote presentations by Werner Baumann, Liam Cond, Bob Reiter and Mike Stern at the Crop Science Summer Technology Showcase on August 1, 2019 in the Bayer Chesterfield Research Center, Missouri, U.S.A.
The document summarizes Bayer's Q2 2019 earnings results. Key points include:
- Sales increased 21% to €11.5 billion (+1% at constant currencies) driven by the Monsanto acquisition.
- EBITDA before special items grew 25% to €2.9 billion with margins up 70 basis points.
- Core EPS increased 6% to €1.62.
- Free cash flow was €751 million, impacted by timing effects from the prior year period.
- Guidance for 2019 was confirmed despite ambitious targets.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
2. Disclaimer
This presentation may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could lead to
material differences between the actual future results, financial situation,
development or performance of the company and the estimates given here.
These factors include those discussed in Bayer’s public reports which are
available on the Bayer website at www.bayer.com.
The company assumes no liability whatsoever to update these forward-looking
statements or to conform them to future events or developments.
Page 2 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
3. Full Year 2011 –
Record Sales And EBIT
Very good year overall, Group targets – that were raised after Q1 –
achieved, proposed DPS of €1.65
Mixed business performance in Q4 – HealthCare and CropScience in line,
MaterialScience below expectations
Excellent innovation pipeline progress: 4 potential blockbuster products
currently launching or expected to be launched near-term at pharma, crop
protection pipeline with €2bn combined peak-sales potential (2011-2015)
Continued Emerging Markets growth: 9% organic business expansion
Productivity largely improved: measures with annualized savings of €543
million implemented
Confident for 2012: Expect higher sales and earnings
Page 3 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
4. 4th Quarter 2011 –
Mixed Business Performance
Q4‘10 Q4‘11 ∆% Highlights of Financial Results
€ million € million
Top-line driven by ConsumerHealth and
Sales 9,012 9,191 +2 (+2)
CropScience
EBITDA
Emerging Markets sales up 5%
- reported 1,510 1,415 -6
- adjusted 1,689 1,541 -9 Improvement of reported EBIT due to
EBIT lower special charges
- reported 51 629 •
Adj. EBITDA declined due to a sharp
- adjusted 1,005 844 -16 drop at MaterialScience
Net income -145 397 •
NCF 1,941 1,152 -41 Net cash flow impacted by payments in
connection with LL Rice (€484m)
oFCF 1,417 427 -70
EPS
- reported -0.18 0.48 •
- core 0.95 0.97 +2
( ) = Fx & portfolio adjusted
Page 4 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
6. Full Year 2011
Targets Achieved
Page 6 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
7. Full Year 2011 –
All Group Targets Achieved
Sales ∆ Fx and portfolio adjusted, EBITDA pre-special items
2011 Outlook 2011 2011
Comments
original actual ∆
4-6% to Raised to 5-7% or €36-37bn
Sales €36.5bn +6%
€35-36bn in Q1
increase
adj.
towards €7.6bn +7% Raised to >€7.5bn in Q1
EBITDA
€7.5bn
Increase by
Core EPS €4.83 +15% Raised to ~15% in Q1
~10%
Net Debt reduce €7.0bn -€0.9bn Record GCF
Page 7 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
8. Full Year 2011 –
Subgroup Performance vs. Targets
2011 Outlook 2011
in € million adj. ∆ Comments
original actual
HealthCare
Targets achieved or exceeded
Sales low/mid single-digit 17,169 +2%
Top-line driven by Consumer
increase
Health
Adj. EBITDA* small improvement 4,702 +7% Pharma margin up 140 bpts.
CropScience
≥ mid-single digit
Sales 7,255 +9%
increase Achieved or exceeded all targets
grow at higher rate
Adj. EBITDA* 1,654 +28%
than sales
MaterialScience Sales growth above, bottom-line
mid single-digit clearly below expectations
Sales 10,832 +8%
increase Pressure from higher raw
grow at higher rate material prices and deteriorating
Adj. EBITDA* 1,171 -14% business environment
than sales
Page 8 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers *Adj. EBITDA = pre-exceptional items
9. Full Year 2011
Significant Progress
Page 9 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
10. Pharma Pipeline –
2011 – Significant Progress Achieved
Project Indication Peak sales Status & Targets
potential
Xarelto Cardiology / > €2bn SPAF: launched (US, EU, others)
Anticoagulation DVT treatment and sec. prevention: launched
DVT prev. ORS: launched in US
Sec. prev. ACS: filed
VEGF Trap- Ophthalmology / ≥ €1bn Filed for wet AMD in EU and Japan
Eye Inhibition of blood Phase III for DME and wet AMD (China)
vessel growth initiated
Positive phase III data in CRVO
Alpharadin Oncology / ≥ €1bn CR prostate cancer: 44% improvement of OS
Targeting of bone Fast track designation by FDA
metastases Filing target: mid 2012
Regorafenib Oncology / ≥ €1bn Metastatic colorectal cancer: 29%
Oral multi-kinase improvement of OS
inhibition Fast track designation by FDA
Filing target: 1H 2012
SPAF: stroke prevention in atrial fibrillation; DVT: deep vein thrombosis; ORS: orthopedic surgery;
ACS: acute coronary syndrome; AMD: age-related macular degeneration; DME: Diabetic macular edema
CRVO: central retina vein occlusion; CR: castration refractory; OS: overall survival
Page 10 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
12. Emerging Markets –
Sales Growth Well Above Global Average
Full Year 2011 Group sales by region Emerging Economies
+5%
USA Emerging
+3% Economies¹ ~5,100
+9% +12%
19% 36%
~4,300
+12%
~2,100
+9%
34% 11% ~1,800
Western Europe Others²
+4% +4%
Group €36,528m; +6% Emerging Latin Eastern Africa &
Asia³ America Europe Middle East
¹ Emerging economies include: Latin America, Asia w/o Japan, Australia,
In € million, ∆% yoy Fx adjusted New Zealand, Africa and Middle East incl. Turkey, Eastern Europe
² Others = Japan, Australia, New Zealand, Canada
³ Emerging Asia = Asia w/o Japan, Australia, New Zealand
Page 12 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
13. Emerging Markets –
Realizing The Opportunity
Fx & portfolio adjusted
Examples 2011 sales development 2011
Hired add. ~1,000 sales reps in China
Relocated primary care headquarter to China
HealthCare Established 50/50 JV w. Zydus Cadila in India
In-licensed Tedizolid antibiotic from Trius for
+10%
several EM markets, incl. China
Opened new “seed treatment application
CropScience center” in Brazil
Approval of LibertyLink soybean, Argentina
+11%
Opened new world-scale TDI plant in China
MaterialScience with innovative gas-phase phosgenation
Moved polycarbonates headquarters to China
+7%
Page 13 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
14. Restructuring Program Fully On Track
Contribution by Subgroup Target: €800m annual cost savings by
2013
Reinvestment of ~50%
Holding & HealthCare
Admin. ~12% One-time-charges of approx. €1bn of
which €803m booked in 2010/11
~54%
Plans include staff reductions of 4,500
€800m
2,500 new hires in growth and
34% innovation, particularly in emerging
markets
CropScience
Measures with €543m annualized
savings already implemented by end
of 2011
Page 14 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
15. Full Year 2012
Financial Outlook
Page 15 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
16. Outlook 2012 –
Planning Assumptions
GDP growth by regions Global economic/political risks
in % vs previous year remain high
5 Outlook for economic growth
5.1
4
4.8 marked by uncertainty
3 3.3 Positive signals for North America,
2 2.6 in Europe we expect slower
1.7 expansion in 2012 than 2011
1
0.7
Asian emerging markets continue to
drive growth
$/€ 1.40, 1% appreciation of Euro
lowers sales by ~€76m and EBITDA
by ~€23m
Crude oil: average $110/bbl
Page 16 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
17. Outlook 2012 –
Planning Assumptions
Expected 2012 Global Market Development
2011 Group sales 10 % OTC-pharma
break-down in % Low- to mid-single digit growth
3 % Diabetes care
low-single digit growth
27 % Rx-pharma
Mid-single digit growth, driven by
emerging markets
3 % Animal Health
Moderate growth
20 % Agrochemicals/Seeds
Positive development
15 % Others
5 % Furniture/wood 6 % Automotive
Robust growth
Ongoing recovery,
small growth
6 % Construction 5 % Electro/electronic
Ongoing recovery Robust growth
Page 17 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
18. Full Year 2012 Outlook Projects Further
Growth And Higher Earnings
Sales ∆ Fx and portfolio adjusted, EBITDA pre-special items
2011 ∆ vs. 2010 2012E
Sales +~3% or
€36.5bn +6%
(Fx & portf. adjusted) ~€37bn*
adj. EBITDA €7.6bn +7% Slightly improve
Core EPS €4.83 +15% Slightly improve
*Assuming Fx rate of $1.40 per €
Outlook depends on specific planning assumptions
as detailed in the Annual/ Quarterly Report
Page 18 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers
19. Full Year 2012 –
Guidance By Subgroup
Expect sales to increase by low- to mid-single-digit
HealthCare percentage. Plan to slightly improve adj. EBITDA .
Expect sales to remain stable or move slightly higher, and adj.
Pharma EBITDA to approx. match prior year level.
Consumer Anticipate mid-single-digit percentage growth of sales and
Health adj. EBITDA.
Plan to grow above market and to increase sales and adj.
CropScience EBITDA by mid-single-digit percentages.
Expect sales and adj. EBITDA to remain level with prior year.
Should market develop more favorably than anticipated, we
MaterialScience expect sales and earnings to increase accordingly.
Q1’12: Expect sales to be roughly level with Q4’11 and adj.
EBITDA to be well above Q4’11 but below Q1’11.
Sales ∆ Fx and portfolio adjusted, EBITDA pre-special items Outlook depends on specific planning assumptions
Page 19 • FY/Q4 2011 Investor Conference Call • Marijn Dekkers as detailed in the Annual/ Quarterly Report